[-2548G/A functional polymorphism in the promoter region of leptin gene and antipsychotic agent-induced weight gain in schizophrenic patients: a study of nuclear family-based association].
OBJECTIVE
To investigate whether there is association between the-2548G/A functional polymorphism in the promoter region of leptin gene and weight gain following antipsychotic agents (APS) acute treatment in schizophrenic patients.


METHODS
Eight-four Chinese Han untreated schizophrenia patients in 70 nuclear families were recruited. The polymorphism of leptin gene was determined with PCR-RFLP technique. Body weight was measured in the patients on admission the and after 10 weeks treatment with risperidone or chlorpromazine.


RESULTS
There was an average (8.00+/-6.13)% increases in baseline weight after the 10 week treatment. There were significant differences in the distribution of allele frequencies (chi2=4.031, P=0.045) between the patients with weight changed >or=7% and <7% subgroups. Family-based association analysis further confirmed the above significant finding by transmission disequilibrium test but not by quantitative trait transmission disequilibrium test.


CONCLUSIONS
The finding confirms that the-2548G/A polymorphism in promoter region of leptin gene is associated with APS-induced weight gain.
Mou
Xiao-dong
XD
Department of Neurology, Affiliated Zhongda Hospital, Southeast University, Nanjing, China.
Zhang
Zhi-jun
ZJ
Zhang
Xiang-rong
XR
Shi
Jia-bo
JB
Sun
Jing
J
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005192:Family Health; D005260:Female; D005838:Genotype; D006801:Humans; D020738:Leptin / Q000235:genetics*; D008297:Male; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D011401:Promoter Regions, Genetic / Q000235:genetics; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D015430:Weight Gain / Q000187:drug effects* / Q000235:genetics
D014150:Antipsychotic Agents; D020738:Leptin